If you’ve been keeping up with the news surrounding the medication Mounjaro, or if you’ve taken it yourself, you probably know that there have been serious concerns about its side effects.
These side effects have led a group of people to start the Mounjaro stomach paralysis lawsuit, which is still ongoing.
Here is a very detailed timeline of events on the Mounjaro stomach paralysis lawsuit:
January 2025: The Case Keeps Expanding
As we move into 2025, the lawsuits against Eli Lilly continue to grow. The MDL now includes even more plaintiffs, and there are hundreds of lawsuits still going through the courts. Eli Lilly has not recalled Mounjaro yet, and many people are still dealing with the painful side effects caused by the drug.
With even more lawsuits being filed and important trials set for late 2025, the outcome of these cases could have a huge impact on how the whole legal process goes. There’s also a growing concern about a possible link between GLP-1 drugs like Mounjaro and cancer, especially thyroid cancer.
A study from France has raised alarms about the risk of cancer in people who have used these drugs for a long time, which could lead to even more lawsuits against Eli Lilly and other drugmakers.
December 2024: Important Court Hearing
On December 16, 2024, an important court hearing took place where Eli Lilly tried to get the lawsuits dismissed. They argued that federal law should stop state law from making claims about the drug’s warnings. This decision could have a big impact on whether the lawsuits move forward or get thrown out.
Around the same time, new research came out that raised concerns about the acidity of Mounjaro. The drug is much more acidic than things like tomato juice, and some researchers worried this could cause tooth decay and damage to teeth. This added another layer of concern about the drug’s safety.
November 2024: Lawsuits Continue to Rise
By November 2024, the number of Mounjaro lawsuits had grown to 1,000. People were claiming even more serious side effects, including blood clots, vision loss, and stomach issues. The lawsuits kept moving forward, with more people seeking justice for the harm caused by the drug.
October 2024: More People Use Mounjaro
In October 2024, the shortage of Mounjaro was finally over, so the drug became widely available again. But this also raised concerns. As more people started using Mounjaro, there were fears that even more people would experience its serious side effects, meaning the number of lawsuits could keep growing.
At the same time, the FDA issued a warning about compounded versions of GLP-1 drugs, like Mounjaro. Some pharmacies had started making their own versions of the drug because of the previous shortage. The problem with these compounded drugs is that they aren’t tested for safety by the FDA, which makes them riskier for patients.
September 2024: Lawsuits Keep Growing
By September 2024, the number of lawsuits had risen sharply. Many of these cases involved serious stomach issues like blood clots, vision loss, and gastroparesis.
One lawsuit involved a 46-year-old woman from Alabama who said she had serious stomach problems after using Mounjaro. She claimed that if her doctor had told her about the drug’s dangerous side effects, she never would have used it.
August 2024: Lawsuits Explode
By August 2024, the number of lawsuits increased drastically. The case became part of the MDL, meaning hundreds of lawsuits against Eli Lilly and other companies making similar drugs (called GLP-1 agonists) were now being handled together.
As more cases piled up, Eli Lilly was ordered to hand over millions of pages of documents related to the development and marketing of Mounjaro.
August 2024: Science Day
The court held a special day called Science Day, where plaintiffs (the people suing) had the chance to explain the science behind how Mounjaro works in the body. This was a very important day, as it showed how Mounjaro might be linked to gastroparesis and other dangerous side effects. It also raised questions that would need to be answered in the following months.
